IL10 and non-small cell lung carcinoma: Despite the prevalence of low IL-2 and IL-10 levels in most patients with late-stage NSCLC prior to receiving PD-1 inhibitors, the cutoff value was hard to determine and was, thus, not taken into account in the analysis.